Former President Donald Trump has indicated that new tariffs on pharmaceuticals and semiconductors are set to be announced soon, with the potential for rates as high as 250%. This move comes alongside a broader push for increased manufacturing in the United States. The pharmaceutical industry has been preemptively responding to these threats, as many drugmakers invest billions into US production. However, experts warn that such tariffs could complicate the supply chain and may not lead to lower drug prices as intended. The situation is further complicated by a new US-EU trade deal that imposes tariffs on medicines, raising concerns about the impact on drug availability and costs for American consumers. As uncertainty grows around this policy, stakeholders from the pharmaceutical sector are preparing for the potential fallout.